SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin surges on inking distribution pact with Scope Ophthalmics

01 Oct 2024 Evaluate

Lupin is currently trading at Rs. 2193.05, up by 2.85 points or 0.13% from its previous closing of Rs. 2190.20 on the BSE.

The scrip opened at Rs. 2186.45 and has touched a high and low of Rs. 2207.65 and Rs. 2175.25 respectively. So far 9505 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2312.00 on 05-Sep-2024 and a 52 week low of Rs. 1113.00 on 31-Oct-2023.

Last one week high and low of the scrip stood at Rs. 2238.00 and Rs. 2160.60 respectively. The current market cap of the company is Rs. 100143.98 crore.

The promoters holding in the company stood at 46.98%, while Institutions and Non-Institutions held 46.10% and 6.92% respectively.

Lupin has inked a distribution pact with Ireland-based Scope Ophthalmics to market a product range, indicated for the treatment of various eye conditions, in Mexico. The company has signed a distribution agreement with Scope Ophthalmics for the registration and marketing of Moist Heat Mask, a Tea Tree Oil Eyelid Cleansing Gel and Tea Tree Oil Eyelid Wipes of the Optase range in Mexico. The products are used for eye conditions like dry eyes, blepharitis and meibomian gland dysfunction (MGD).

Through the signature of this collaboration with Lupin, Scope is expanding its footprint in Latin America. 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2303.70 -7.20 (-0.31%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×